Acne vulgaris, better known as acne, is the most common skin condition in the US, according to the American Academy of Dermatology (AAD), affecting up to 50 million Americans annually. About 85% of ...

The trial was conducted by Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to ...

A few things happen when you get a corticosteroid injection at the dermatologist’s office. “We inject it into active inflamed ...

Step into your local drugstore and you’ll come across countless cleansers, serums, lotions and masks all promising the same thing: fewer acne breakouts and clearer, smoother skin. Unfortunately, not ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. 90% of patients reported slight to high satisfaction in ...

ORLANDO, Florida — Two lasers developed specifically to target the sebaceous gland were cleared by the US Food and Drug Administration (FDA) for the treatment of acne vulgaris in 2022, but it is ...

Denifanstat met all primary and secondary endpoints versus placebo and was generally well tolerated in a Phase 3 clinical ...